Alamar Biosciences (ALMR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.20
- Estimate
- -$0.32
- Surprise
- +37.4%
- Revenue (period 2026-06-30)
- $29.4M
- Score at report (before → after)
- 5.4 → 5.4/10
Revenue source: xbrl.
How the report landed
Alamar Biosciences (ALMR) reported a narrower loss than forecast — adjusted EPS of -$0.20 against the -$0.32 estimate (a 37.4% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALMR Hold at 6.0/10.
1 of the last 1 quarters beat the estimate; this quarter's +37.4% surprise compares with a +37.4% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
- Negative momentum
- Momentum score 1.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $23.53
- Price target
- $30.80
- Stop
- $22.59
- Upside to target
- +30.9%
- Reward-to-risk
- 2.1:1
Model outputs from TrendMatrix’s engine as of 2026-10-13 — shown for context, not personalized investment advice.
ALMR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.68B
- P/E (fwd)
- -44.7
- 52-week range
- $18.85–$39.61
- Off 52-week high
- 40.6%
- RSI (14)
- 33
- Volume vs avg
- 0.43×
- Score today
- 6.0/10